# Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

> **NCT02728895** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 24 (actual)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT02728895
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-15
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-07-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728895, "Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02728895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*